A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
REGULATORY
MHLW to Continue to Suspend HPV Vaccine Recommendation
The Ministry of Health, Labor and Welfare (MHLW) will maintain the suspension of its active recommendation for cervical cancer vaccines after a follow-up survey found that 186 girls who experienced post-vaccination symptoms have not yet recovered. Two MHLW panels advised…
To read the full story
Related Article
- MSD Renews Call for Reinstating Govt’s HPV Vaccine Promotion after WHO Statement
January 15, 2016
- Active Promotion of HPV Vaccines Should Be Resumed: GSK
October 1, 2015
- Can’t Give Timeline for Active Recommendation for HPV Vaccines, Expert Discussions Eyed: Govt
September 8, 2015
- MHLW to Issue Notification with Survey Form on Adverse Reactions to HPV Vaccines
October 31, 2014
- MHLW to Reinforce Follow-Up Surveys on HPV Vaccine Recipients
September 1, 2014
- Ministry Joint Panel Says Evidence Linking HPV Vaccine Adjuvant with Side Effects Weak
February 27, 2014
- HPV Vaccine Injection Site Pain Possible Cause of Chronic Pain: MHLW Subcommittees
January 21, 2014
- Active Recommendation for HPV Vaccines Remains Suspended
December 26, 2013
- Health Ministry Subcommittees Agree to Continue Suspending Recommendation for HPV Vaccines
October 30, 2013
REGULATORY
- Govt Must Not Let Pro-Innovation Reform of 2024 Go to Waste: Sr Vice Minister
January 15, 2025
- Nothing Decided on Drug Discovery Support Fund: Minister
January 15, 2025
- MHLW Calls for Proper Use and Ordering of Flu Drugs amid Outbreak
January 14, 2025
- MHLW Starts Inviting Subsidy Applications for Ramp-Up of Key Drugs
January 14, 2025
- MHLW Plans to Submit 6 Bills in 2025 Ordinary Diet Session
January 14, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…